Abstract:Background: Both estrogen receptor a (ER-a) and progesterone receptor (PR) are good prognostic factors and indicators of benefit from endocrine therapy in breast cancer patients. The relationship of the ER-alpha and PR status and the difference in clinical benefit from endocrine therapy in breast cancer is currently unclear. It has been suggested that keratinocyte growth factors (KGFs) are important regulatoty factors in breast cancer. Our laboratory has demonstrated that KGF call act as an estromedin for the stimulation of breast cancer cell growth. Also, KGF stimulates aromatase activity in primary cultured human breast cells. This enzyme is a key to the conversion of androgens to estrogens. In the present study, ER-alpha, two estrogen regulated genes, PR and PTP gamma, KGF and their relationship with endocrine resistance in human breast cancer cells were investigated.Materials and Methods: MCF-7 cells were treated with KGF (1, 5, 10, 20 ng/ml), KGF-13 (0.1, 1, 10 mu M) or vehicles as control for 24 hours. KGF-13 is a potential receptor-binding pentapeptide constructed using the KGF peptide residues 101-105 (RTVAV) as a template, located within the beta 4 - beta 5 loop. Total RNA were isolated and real-time PCR was employed to identify ER-a, PR and PTP gamma gene expressions in response to KGF and KGF-13. Western blot analysis was used to verify the levels of ER-a and PR protein, whereas inummohistochemical staining was used to detect PTP gamma expression in MCF-7 cells. To determine the response of MCF-7 cells to endocrine therapy, MCF-7 was treated with either 20 ng/ml KGF or 10 mu M KGF-13 combined with 1, 3 and 5 mu M of 4-hydroxytamoxifen (4011-Tam). A non-radioactive cell proliferation assay was applied to determine the growth rate of MCF-7 cells. The results of real-time PCR and the cell proliferation assay were analyzed by Student's t-test and p-values of less than 0.05 were considered statistically significant.Results: Our data showed that KGF significantly suppressed ER-a, PR and PTP gamma expression in MCF-7 cells. KGF suppressed ER-a, PR and PTP gamma mRNA to a maximal inhibition at 20 ng/ml by 88%, 57% and 61%, respectively. Western blot analysis and immuno-histochemical staining confirmed the down-regulation of ER-a, PR and PTP gamma by KGF in protein levels. Ten mu M KGF-13 also decreased ER-alpha expression. Teti mu M KGF-13 significantly decreased ER-alpha, PR and PTP gamma mRNA expressions by 51%, 57% and 67%, respectively. These KGF-13-mediated mRNA down-regulations were also observed in protein levels. In a cell proliferation assay, 40H-Tam (3, 5 mu M) induced MCF-7 cell death. KGF and KGF-13 alone did not stimulate MCF-7 cell growth. KGF significantly disrupted 40H-Tam cell killing effects by 1.2- and 1.3-fold at 40H-Tam concentrations of 3 mu M and 5 mu M. respectively. KGF-13 significantly disrupted 40H-Tam cell killing effects by 1.2- and 1.7-fold at 40H-Tam concentrations of 3 mu M and 5 mu M, respectively.Conclusion: Our results suggested that not only ER-alpha and PR but also PTP gamma could be potential bio-makers for growth factor-induced endocrine resistant in breast cancer. KGF might increase the endocrine resistance via decreasing ER-alpha, PR and PTP gamma as well Moreover, the functional analysis of KGF-13 implied possible applications of using short receptor-binding peptides derived from intact KGF as breast cancer therapeutic agents. Thus, our experimental data provided evidence of KGF-induced anti-hormone resistance in human breast cancer and suggested novel strategies for breast cancer via interference with KGF signaling.

Interplay of nuclear receptors (ER, PR, and GR) and their steroid hormones in MCF-7 cells

The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells

Effect of Proliferation, Cell Cycle, and Bcl-2s of MCF-7 Cells by Resveratrol

High Levels of Progesterone Receptor B in MCF-7 Cells Enable Radical Anti-Tumoral and Anti-Estrogenic Effect of Progestin

The Divergent Effects of Ovarian Steroid Hormones in the MCF-7 Model for Luminal A Breast Cancer: Mechanistic Leads for Therapy

Abstract 6281: Context dependent role of glucocorticoids in breast cancer

TRPS1 Regulates the Opposite Effect of Progesterone Via RANKL in Endometrial Carcinoma and Breast Carcinoma

OR05-04 Steroid Receptor Co-Activators Complexes Cooperate with Progesterone Receptors (PR) to Reprogram Metabolic Pathways that Drive Therapy Resistant Populations in ER+ Breast Cancer

Estrogen receptor alpha (ERα) driven trans-regulation of mitotic checkpoint complex (MCC) components affects the clinical outcome of breast cancer

Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells

Abstract 3080: Characterization of steroid receptor mediated activation of GLI as driving force of breast cancer growth

Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

Estrogen Receptor Α Mediates Proliferation of Breast Cancer MCF–7 Cells Via a P21/pcna/e2f1‐dependent Pathway

Glucocorticoid Receptor:MegaTrans Switching Mediates the Repression of an ERα-Regulated Transcriptional Program.

Effects of exogenous ER β expression on the cell growth properties of MCF-7 breast cancer cell line

Mechanistic Regulation of Epidermal Growth Factor and Hormonal Receptors by Kinase Inhibitors and Organofluorines in Breast Cancer Therapy

Abstract 5364: Progesterone receptor modulates the antigen processing and presentation machinery decreasing MHC class I expression on tumors

Keratinocyte Growth Factor (KGF) Induces Tamoxifen (tam) Resistance in Human Breast Cancer MCF-7 Cells.

ER status in adriamycin-sensitive and adriamycin-resistant MCF-7 human breast cancer cell lines

A Novel Combinatorial Epigenetic Therapy Using Resveratrol and Pterostilbene for Restoring Estrogen Receptor-α (ERα) Expression in ERα-Negative Breast Cancer Cells

Functional Study of Progesterone Receptor Isoforms in Endometrial Cancer Cell Lines